ArticleFrontiers in medicine2025
Chrysin attenuates intervertebral disk degeneration via dual inhibition of matrix metalloproteinases and senescence: integrated network pharmacology, molecular docking, and experimental validation.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intervertebral disk degeneration (DDD) caused by nucleus pulposus cell (NPCs) senescence, oxidative stress, and extracellular matrix (ECM) degradation is one of the leading causes of chronic low back pain, yet effective treatments remain elusive. This study investigated the potential of chrysin, a natural flavonoid with antioxidant and anti-inflammatory properties, to alleviate NPCs aging and ECM dysregulation. Through network pharmacology, researchers identified 89 overlapping targets between chrysin and DDD, including MMP2, MMP9, and TGFB1. Enrichment analyses revealed key pathways in cancer, such as JAK-STAT signaling, efflux cells, and central carbon metabolism. Molecular docking showed that chrysin has a strong binding affinity for MMP2 (-8.4 kcal/mol) and MMP9 (-8.2 kcal/mol), key enzymes for ECM degradation. Molecular dynamics simulations demonstrated that the Chrysin-MMP-9 and Chrysin-MMP-2 complexes exhibited favorable dynamic properties. Experimental validation in H2O2-induced senescent NPCs confirmed the protective effects of chrysin: pretreatment with chrysin (1 μM) significantly reduced senescence-associated β-galactosidase activity and inhibited MMP2/9 mRNA expression while restoring collagen II and aggrecan levels. In addition, Chrysin attenuated oxidative stress-mediated ECM damage, which was consistent with network predictions. These findings highlight the dual ability of Chrysin to inhibit MMP activity and combat aging, making it a promising multi-targeted therapeutic candidate for the treatment of DDD. This study combines bioinformatics with experimental modeling to mechanistically reveal the anti-aging mechanism of Chrysin.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.